GSE115643 CTB 0 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE115643_CTB_0_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE115643_CTB_0_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE115643_CTB_0_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE115643_CTB_0_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

cytochrome P450 family 2 subfamily B member 7, pseudogene

Gene

family with sequence similarity 106 member A

Gene

THAP9 antisense RNA 1

Gene

SBDS pseudogene 1

Gene

urothelial cancer associated 1

Gene

PAXX non-homologous end joining factor

Gene

pleckstrin homology and RUN domain containing M1 pseudogene 1

Gene

MT-ND2 pseudogene 28

Gene

SVIL antisense RNA 1

Gene

TGF-beta induced TARBP2 interacting lncRNA

  • Gene

    cytochrome P450 family 2 subfamily B member 7, pseudogene


  • Gene

    family with sequence similarity 106 member A


  • Gene

    THAP9 antisense RNA 1


  • Gene

    SBDS pseudogene 1


  • Gene

    urothelial cancer associated 1


  • Gene

    PAXX non-homologous end joining factor


  • Gene

    pleckstrin homology and RUN domain containing M1 pseudogene 1


  • Gene

    MT-ND2 pseudogene 28


  • Gene

    SVIL antisense RNA 1


  • Gene

    TGF-beta induced TARBP2 interacting lncRNA

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.